

Article

Subscriber access provided by American Chemical Society

Solid-Phase Synthesis of 1,2-Diheterocyclic-Substituted (E)-Olefins from a Supported Selenium Resin

Wei-Ming Xu, Xian Huang, and E. Tang

J. Comb. Chem., 2005, 7 (5), 726-733• DOI: 10.1021/cc050044+ • Publication Date (Web): 04 August 2005

Downloaded from http://pubs.acs.org on March 22, 2009

More About This Article

Additional resources and features associated with this article are available within the HTML version:

- Supporting Information
- Links to the 5 articles that cite this article, as of the time of this article download
- Access to high resolution figures
- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article

View the Full Text HTML



Solid-Phase Synthesis of 1,2-Diheterocyclic-Substituted (E)-Olefins from a Supported Selenium Resin

Wei-Ming Xu,^{†,‡} Xian Huang,^{*,†} and E. Tang[†]

Department of Chemistry and Center of Analysis and Measurement, Zhejiang University, Hangzhou, 310028, P. R. China

Received April 5, 2005

A library of 1,2,3-triazoles, isoxazoles, 1,2,4-oxadiazoles, and isoxazoline-containing 1,2-di-heterocyclicsubstituted compounds with three points of diversity linked by an *E* double bond were prepared. Key steps include a 1,3-dipolar cycloaddition and Porco's two-step, one-pot condensation and α -alkylation reaction of selenium resins.

Introduction

The preparation of diverse libraries of organic compounds is an important facet of modern drug discovery programs. One of the most commonly employed methods in library production is solid-phase organic synthesis (SPOS).¹ The field of solid-phase heterocyclic chemistry has rapidly expanded because experience has shown that compounds with biological activity are often derived from heterocyclic structures. Synthesis methods that enable the rapid production of arrays of heterocycles, useful for the identification of new lead structures, are of critical importance to the pharmaceutical industry.²

Isoxazoles and isoxazolines represent two classes of pharmacophores that are observed in many therapeutic agents,³ while oxadiazoles are important bioisosters for esters and amides in drug discovery with reported muscarinic agonist, 5-HT agonist, benzodiazepine receptor agonist, and antirhinoviral activities.⁴ Several members of the 1,2,3triazole family have also shown interesting biological properties, such as antiallergic, antibacterial, and anti-HIV activity.5 Therefore, they are all interesting targets which potentially can be made via solid-phase chemistry.⁶ Although the solidphase synthesis of 1,2,3-triazoles via 1,3-dipolar cycloaddition is well developed,6d,7 the one-pot 1,3-dipolar cycloaddition through aryl halides, alkynes, and sodium azide on the solid phase to synthesize 1,2,3-triazole is first developed. A one-pot methodology that avoids the isolation of organic azides is desirable for low molecular weight organic azides as they are unstable and difficult to handle;⁸ sometimes that would be especially true for small molecules with several azide functionalities that would be of much interest for the generation of polyvalent structures. The incorporation of 1,2,3-triazoles or isoxazoles or 1,2,4-oxadiazoles and isoxazoline into a bis-ring system linked by a double bond could

[†] Department of Chemistry.

be useful as di-heterocyclic substituted compounds⁹ have been rarely investigated.

An important aspect of the solid-phase methodology is the choice of the linker, which is crucial for the attachment and detachment of the requisite substrates to and from the resin. Many solid-phase syntheses rely on the release of carboxylic acids, esters, ethers, and amides from an esteror amide-bound substrate. Alternative methods that allow the cleavage of resin, with access to more variable functionalities, are extremely desirable.^{10,11} Since the first organoselenium resin¹² was reported in 1976, several groups have developed organoselenium resins as convenient linkers.^{13,14} Recently, our research group has been interested in the application of organic selenium resins in organic synthesis.^{10,15} Herein we report the preparation of a library of bisheterocyclic-containing compounds linked by a double bond (E) with the advantages of straightforward operation, lack of odor, stability, and good resulting purity of the product. It is noteworthy that the polystyrene-supported selenium resins used here assist the crucial reaction of α -alkylation and selenoxide syn-elimination, which ensures the purity of the products and introduces a new E double bond into the target molecules.

Results and Discussion

Efforts began from polystyrene-supported selenenyl bromide 1^{13} (dark-red resin, Br: 0.99 mmol/g), which was treated with NaBH₄ and propargyl bromide to give the corresponding white resin **2**.¹⁰ Resin **2** reacted smoothly with aryl halides and sodium azide through a one-pot 1,3-dipolar cycloaddition¹⁶ catalyzed by CuI and proline to furnish polystyrene-supported 1,2,3-triazolyl-substituted selenium resin **3** (FTIR: 1635 cm⁻¹ with disappearance of 3299 cm⁻¹; Scheme 1).

The α -alkylation of **3** by base treatment and addition of substituted allyl bromides was investigated. It was found that by keeping the reaction temperature at -70 °C and using 1.2 equiv of LDA, 4.0 equiv of substituted allyl bromide

^{*} Corresponding author. Phone: +86-571-88807077. Fax: +86-571-88807077. E-mail: huangx@mail.hz.zj.cn.

[‡] Center of Analysis and Measurement.



 a Reagents and conditions: (a) NaBH4, THF/DMF, 40 °C, 6 h then propargyl bromide, 3 h; (b) NaN3, R¹l, proline, Cul, Et3N, DMSO, 65 °C, 12 h.

Table 1. Synthesis of Triazolyl- andIsoxazolinyl-Substituted (E)-Olefins

product	\mathbb{R}^1	\mathbb{R}^2	R ³	yield (%) ^a	purity (%) ^b
6a	C ₆ H ₅	Н	$4-CH_3C_6H_4$	51	89
6b	C_6H_5	Н	$4-FC_6H_4$	47	91
6c	C_6H_5	Н	$4-BrC_6H_4$	58	92
6d	C_6H_5	Н	C_6H_5	66	95
6e	$4-ClC_6H_4$	Н	$4-CH_3C_6H_4$	45	90
6f ^c	C_6H_5	CH3	$4-ClC_6H_4$	43	89
6g ^c	C_6H_5	CH3	$4-CH_3C_6H_4$	49	90

^{*a*} Yield of the crude product based on the loading of the resin **1**. ^{*b*} Determined by HPLC ($\lambda = 287$ nm). ^{*c*} 1,3-Dipolar cycloaddition step performed twice prior to cleavage.

gave the optimal results. The α -alkylated **4** then underwent another 1,3-dipolar cycloaddition to furnish the polystyrenesupported 1,2,3-triazolyl- and isoxazolinyl-substituted selenide resin **5**. It is noteworthy that in this process the sequence of adding the substrates was reversed compared to our previous work;¹⁰ thus, hydroximoyl halide was added dropwise to a mixture of resin **4** and an excess of Et₃N. No product was obtained when Et₃N, was added dropwise. Triazolyl- and isoxazolinyl-substituted olefins **6** were obtained regioselectively through selenoxide *syn*-elimination of resin **5** (Scheme 2). Results are described in Table 1and show that triazolyl- and isoxazolinyl-substituted olefins **6** could be obtained in moderate to good yield with good levels of purity.

On the basis of our previous work,¹⁰ polystyrene-supported isoxazolyl-substituted selenium resin **7** underwent α -alkyl-ation and 1,3-dipolar cycloaddition smoothly, which was followed by selenoxide *syn*-elimination to obtain isoxazolyl-and isoxazolyl-substituted olefins **10** (Scheme 3). The results are summarized in Table 2.

Scheme 2^a

Table 2.	Synthesis c	of Isoxazoly	I- and
Isoxazolii	yl-Substitu	ted Olefins	

product	\mathbb{R}^1	R ²	R ³	yield (%) ^a	purity (%) ^b
10a	4-ClC ₆ H ₄	C_6H_5	COOEt	75	93
10b	$4-CH_3C_6H_4$	C_6H_5	COOEt	77	91
10c	$4-CH_3C_6H_4$	C_6H_5	$4-ClC_6H_4$	64	89
10h	$4-ClC_6H_4$	C_6H_5	$4-CH_3C_6H_4$	66	94
10e	$4-CH_3C_6H_4$	Н	$4-FC_6H_4$	61	90
10f	$4-ClC_6H_4$	C_6H_5	$4-FC_6H_4$	57	96

^{*a*} Yield of the crude product based on the loading of the resin **1**. ^{*b*} Determined by HPLC. ($\lambda = 287$ nm).

The scope of the products is of upmost importance in the solid-phase organic synthesis; thus, besides 1,3-dipolar cycloadditions,¹⁷ Porco's condensation¹⁸ is also an important method to prepare 1,2,4-oxadiazoles. Although 1,2,4-oxadiazoles are biologically interesting compounds, their preparation on solid phase is relatively rare.^{6c,19}

Thus, polystyrene-supported selenenyl bromide 1^{13} (darkred resin, Br: 0.99 mmol/g) was treated with NaBH₄ and α -bromoacetic acid to give the corresponding white resin 11^{15d} almost quantitatively (Br was undetectable) while the reaction was monitored by FT-IR, which showed a strong peak for the carbonyl absorptions at 1700 cm⁻¹. It was also found that resin **11** reacted smoothly with amidoxime and DCC through Porco's two-step, one-pot condensation to furnish polystyrene-supported oxadiazolyl-substituted selenium resin **12** (FTIR: 1653 cm⁻¹ with disappearance of the band at 1700 cm⁻¹; Scheme 4).

The potential α -alkylation with LDA and substituted allyl bromides was also investigated. It should be noted that during this step higher temperatures or excessive base (LDA) would result in the di-allylation of the selenide resin **12**, and thus, it was found that keeping the reaction temperature at -60°C and 1.2 equiv of LDA, 4.0 equiv of substituted allyl bromide gave the optimal results. The α -alkylated selenium resin **13** was used in a 1,3-dipolar cycloaddition to furnish polystyrene-supported oxadiazolyl- and isoxazolinyl-substituted selenium resin **14**. Oxadiazolyl- and isoxazolinylsubstituted olefins **15** were obtained stereoselectively through selenoxide *syn*-elimination from resins **14** (Scheme 5).



^{*a*} Reagents and conditions: (a) LDA (1.2 equiv), THF, -70 °C, 1.5 h; substituted allyl bromide (4 equiv), THF, -70 to -50 °C, 1 h; (b) R³CH=NOH (4 equiv), NCS (4 equiv), CH₂Cl₂, Et₃ N, (20 equiv), rt, 12 h; (c) H₂O₂, THF, 0 °C, 1 h, then rt, 20 min.

Scheme 3^a



^{*a*} Reagents and conditions: (a) LDA (1.2 equiv), THF, $-60 \circ C$, 1.5 h; substituted allyl bromide (4 equiv), THF, $-60 \circ C$, 1 h; (b) R₃CH=NOH (3 equiv), NCS (3 equiv), CH₂Cl₂, Et₃ N, (6 equiv), rt, 24 h; (c) H₂O₂, THF, $0 \circ C$, 1 h, then rt, 20 min.

Scheme 4^a



 a Reagents and conditions: (a) NaBH4, THF/DMF, 40 °C, 6 h then BrCH2COOH, 3 h; (b) DCC, R^1C(NH2)=NOH, 1,4-dioxane.

Table 3. Synthesis of Oxadiazolyl- and Isoxazolinyl-Substituted (*E*)-Olefins

				yield	purity
product	\mathbb{R}^1	\mathbb{R}^2	R ³	(%) ^a	$(\%)^{b}$
15a	$4-CH_3C_6H_4$	Н	$4-ClC_6H_4$	64	93
15b	$4-FC_6H_4$	C_6H_5	$4-CH_3C_6H_4$	51	90
15c	$4-CH_3C_6H_4$	Н	COOEt	71	95
15d	$4-CH_3C_6H_4$	C_6H_5	COOEt	69	89
15e	$4-CH_3C_6H_4$	C_6H_5	$4-BrC_6H_4$	60	92
15f	$4-CH_3C_6H_4$	C_6H_5	$4-ClC_6H_4$	59	90
15g	$4-CH_3C_6H_4$	C_6H_5	$4-CH_3C_6H_4$	64	93
15h	$4-FC_6H_4$	C_6H_5	COOEt	61	93
15i	C_6H_5	Н	COOEt	70	96
15j	C_6H_5	Н	$4-ClC_6H_4$	63	90
15k	C_6H_5	Н	$4-CH_3C_6H_4$	64	95
15 l	C_6H_5	Н	$4-CH_3OC_6H_4$	68	89
15m	$4-ClC_6H_4$	C_6H_5	$4-CH_3C_6H_4$	57	90
15n	$4-ClC_6H_4$	Н	$4-ClC_6H_4$	60	95
150	$4-ClC_6H_4$	C_6H_5	$4-BrC_6H_4$	66	91
15p	$4-ClC_6H_4$	Н	COOEt	72	95
15q	$4-ClC_6H_4$	Н	$4-CH_3OC_6H_4$	65	91
15r	$4-ClC_6H_4$	C_6H_5	$4-O_2NC_6H_4$	48	87
15s	$4-ClC_6H_4$	C_6H_5	COOEt	70	97

^{*a*} Yield of the crude product based on the loading of the resin **1**. ^{*b*} Determined by HPLC ($\lambda = 287$ nm).

Results are described in Table 3 and show that oxadiazolyland isoxazolinyl-substituted olefins **15** were obtained in moderate to good yield with good purity.

It is noteworthy that in all these processes only the alkylated resins 5, 9, and 14 underwent selenoxide *syn*-elimination under mild cleavage conditions (Schemes 2, 3, and 5 step c). No reaction was observed for the unalkylated resins 3, 7, and 12 under the same conditions, which thus ensures the purity of the crude products in a "safely catch linker" type of approach.

In summary, we developed a solid-phase method to prepare libraries of 1,2,3-triazoles, isoxazoles, 1,2,4-oxadiazoles, and isoxazoline-containing di-heterocyclic-substituted compounds linked via an *E* double bond. The polystyrene-supported selenium resins used here not only facilitate the separation of the products, but also assist in the crucial reaction of α -alkylation and selenoxide *syn*-elimination, which ensures the purity of the products liberated from the resin.

Scheme 5^a

Experimental Section

General Methods. Starting materials were obtained from commercial suppliers and used without further purification. THF was distilled from sodium/benzophenone immediately prior to use. Polystyrene (H 1000, 100-200 mesh, crosslinked with 1% divinylbenzene) was used for the preparation of selenenyl bromide resin (Br: 0.99 mmol/g) according to the procedure described by Nicolaou^{13,14a} and was purchased from Nan-Kai University. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded on a Bruker Avance (400 MHz) spectrometer using CDCl₃ as the solvent and TMS as an internal standard. Mass spectra (EI, 70 eV) were recorded on a HP5989B mass spectrometer. Infrared spectra were recorded on a Shimadzu IR-408 spectrometer. Elemental analyses were performed on a Flash EA1112 instrument. HPLC was performed on an Agilent 1100 (column, ODS 5 μ m 250 × 4 mm; mobile phase, THF/MeOH/H₂O = 50/20/ 30(V/V); flow rate, 0.8 mL/min; detector, UV 287 nm). Samples were purified by TLC for ¹³C NMR and microanalyses.

Typical Procedure for the Preparation of Polystyrene-Supported Triazolyl-Substituted Selenium Resin 3. To a suspension of the swollen polystyrene-supported propargyl selenide resin 2 (1.0 g) in DMSO (10 mL) was added NaN₃ (3.0 mmol), ArI (6.0 mmol), proline (0.5 mmol), CuI (0.5 mmol), and Et₃ N, (0.5 mmol) under nitrogen. The mixture was stirred at 65 °C for 12 h. The resin 3 was collected by filtration, washed with DMF (10 mL \times 2), DMF/0.1 N HCl (3:1) (10 mL \times 2), H₂O (10 mL \times 2), THF (10 mL \times 2), and CH₂Cl₂ (10 mL \times 2), and dried in a vacuum.

Typical Procedure for the Preparation of Triazolyland Isoxazolinyl-Substituted Olefins (Products 6a–g). To a suspension of the swollen resin 3 (0.5 g) in anhydrous THF (15 mL), cooled to -70 °C, was added dropwise LDA (2 M in THF/hexane, 0.3 mL) under nitrogen. After stirring for 1.5 h at -70 °C, a solution of substituted allyl bromide (2 mmol) in anhydrous THF (1 mL) was added. The suspension was stirred for another 0.5 h at -70 °C, being slowly warmed to -50 °C over 0.5 h before quenching with H₂O (1 mL). Resin 4 was collected by filtration, washed with THF (10 mL \times 2), THF/H₂O (3:1) (10 mL \times 2), H₂O (10 mL \times 2), THF (10 mL \times 2), and CH₂Cl₂ (10 mL \times 2), and dried in a vacuum.

To a suspension of the swollen resin 4 (0.5 g) and 10 mmol Et₃N, in CH₂Cl₂ (15 mL) a solution of hydroximoyl halide (4.0 mmol) in CH₂Cl₂ (10 mL) (prepared from 4.0 mmol of aldoxime and 4.0 mmol of NCS stirring at room temperature for 3 h before use) was slowly added dropwise over 3 h. After stirring at room temperature for 12 h, resin **5** was collected by filtration and washed with THF (10 mL \times 2),



^{*a*} Reagents and conditions: (a) LDA (1.2 equiv), THF, -60 °C, 1.5 h; substituted allyl bromide (4 equiv), THF, -60 to -40 °C, 1 h; (b) R³CH=NOH (8 equiv), NCS (8 equiv), CH₂Cl₂, Et₃ N, (10 equiv), rt, 24 h (c) H₂O₂, THF, 0 °C, 1 h, then rt, 20 min.

ether (10 mL × 2), THF/H₂O (3:1) (10 mL × 2), H₂O (10 mL × 2), THF (10 mL × 2), benzene (10 mL × 2), MeOH (10 mL×2), and CH₂Cl₂ (10 mL×2). The washed resin **5** was suspended in THF (15 mL), 30% (aq) H₂O₂ (0.5 mL) was added, and the mixture was stirred at 0 °C for 1 h followed by 20 min at room temperature. The mixture was filtered, and the resin was washed with CH₂Cl₂ (15 mL × 2). The filtrate was washed with H₂O (30 mL × 2), dried over MgSO₄, and evaporated to dryness under vacuum to obtain the crude products **6**. Further purification was via flash chromatography with *n*-hexanes—EtOAc (2:1 v/v) as the eluent for ¹³C NMR and microanalyses.

6a: pale yellow solid, mp 136–138 °C. ¹H NMR (CDCl₃) δ 7.93 (1H, s), 7.72 (2H, d, J = 8.0 Hz), 7.58–7.42 (5H, m), 7.21 (2H, d, J = 8.0 Hz), 6.80 (1H, d, J = 16.0 Hz), 6.63 (1H, dd, $J_1 = 6.8$ Hz, $J_2 = 16.0$ Hz), 5.37–5.34 (1H, m), 3.58 (1H, dd, $J_1 = 10.4$ Hz, $J_2 = 16.4$ Hz), 3.24 (1H, dd, $J_1 = 8.0$ Hz, $J_2 = 16.4$ Hz), 2.38 (3H, s); ¹³C NMR (CDCl₃) δ 156.4, 145.4, 140.4, 136.8, 130.0, 129.7, 129.4, 128.7, 126.6, 126.5, 120.5, 120.4, 118.7, 80.9, 40.9, 21.4; MS m/z 168 (100), 330 (M⁺); IR ν_{max} (cm⁻¹) 3133, 2919, 2850, 1632, 1597, 1500, 1041, 905, 841, 815, 760, 690, 537. Anal. Calcd for C₂₀H₁₈N₄O: C, 72.71; H, 5.49; N, 16.96. Found: C, 72.60; H, 5.55; N, 16.89.

6b: pale yellow solid, mp 125–126 °C. ¹H NMR (CDCl₃) δ 7.94 (1H, s), 7.73–7.66 (4H, m), 7.54–7.46 (3H, m), 7.10 (2H, t, J = 8.6 Hz), 6.80 (1H, d, J = 16.0 Hz), 6.63 (1H, dd, $J_1 = 6.8$ Hz, $J_2 = 16.0$ Hz), 5.41–5.35 (1H, m), 3.58 (1H, dd, $J_1 = 10.6$ Hz, $J_2 = 16.4$ Hz), 3.24 (1H, dd, $J_1 = 8.0$ Hz, $J_2 = 16.4$ Hz); ¹³C NMR (CDCl₃) δ 163.8 (J = 249.3 Hz), 155.4, 145.3, 136.8, 129.7, 128.8, 128.6 (J = 8.4 Hz), 125.6 (J = 3.0 Hz), 120.6, 120.4, 118.8, 115.8 (J = 21.8 Hz), 107.9, 81.2, 40.8; MS m/z 168 (100), 334 (M⁺); IR ν_{max} (cm⁻¹) 3131, 2925, 2852, 1634, 1598, 1501, 932, 823, 761, 690, 539. Anal. Calcd for C₁₉H₁₅FN₄O: C, 68.25; H, 4.52; N, 16.76. Found: C, 68.33; H, 4.47; N, 16.85.

6c: pale yellow solid, mp 166–167 °C. ¹H NMR (CDCl₃) δ 7.93 (1H, s), 7.72 (2H, d, J = 8.0 Hz), 7.55–7.44 (7H, m), 6.81 (1H, d, J = 16.0 Hz), 6.63 (1H, dd, $J_1 = 6.8$ Hz, $J_2 = 16.0$ Hz), 5.38–5.35 (1H, m), 3.57 (1H, dd, $J_1 = 10.4$ Hz, $J_2 = 16.4$ Hz), 3.23 (1H, dd, $J_1 = 8.0$ Hz, $J_2 = 16.4$ Hz); ¹³C NMR (CDCl₃) δ 155.6, 145.2, 136.8, 131.9, 129.7, 129.6, 128.8, 128.3, 128.1, 124.4, 120.7, 120.4, 118.8, 81.4, 40.6; MS m/z 394 (M⁺, 100), 396 (M⁺ + 2, 97); IR ν_{max} (cm⁻¹) 3131, 2920, 2850, 1632, 1599, 1501, 1033, 837, 758, 688. Anal. Calcd for C₁₉H₁₅BrN₄O: C, 57.74; H, 3.83; N, 14.17. Found: C, 57.62; H, 3.91; N, 14.22.

6d: pale yellow solid, mp 111–113 °C. ¹H NMR (CDCl₃) δ 7.97 (1H, s), 7.75–7.69 (4H, m), 7.56–7.43 (6H, m), 6.83 (1H, d, J = 16.0 Hz), 6.66 (1H, dd, $J_1 = 6.8$ Hz, $J_2 = 16.0$ Hz), 5.42–5.37 (1H, m), 3.62 (1H, dd, $J_1 = 10.8$ Hz, $J_2 = 16.4$ Hz), 3.29 (1H, dd, $J_1 = 8.0$ Hz, $J_2 = 16.4$ Hz); ¹³C NMR (CDCl₃) δ 156.4, 136.8, 130.1, 130.0, 129.76, 129.73, 128.81, 128.78, 128.71, 128.68, 126.7, 120.5, 120.4, 80.9, 40.9; MS *m*/*z* 168 (100), 316 (M⁺); IR ν_{max} (cm⁻¹) 3132, 2922, 2851, 1633, 1599, 1501, 1028, 761, 690, 540. Anal. Calcd for C₁₉H₁₆N₄O: C, 72.13; H, 5.10; N, 17.71. Found: C, 72.01; H, 5.18; N, 17.80.

6e: pale yellow solid, mp 145–146 °C. ¹H NMR (CDCl₃) δ 7.90 (1H, s), 7.68 (2H, d, J = 8.0 Hz), 7.58 (2H, d, J = 7.6 Hz), 7.51 (2H, d, J = 7.6 Hz), 7.22 (2H, d, J = 7.6 Hz), 6.80 (1H, d, J = 16.0 Hz), 6.62 (1H, dd, $J_1 = 6.8$ Hz, $J_2 = 16.0$ Hz), 5.37–5.33 (1H, m), 3.58 (1H, dd, $J_1 = 11.2$ Hz, $J_2 = 16.4$ Hz), 3.24 (1H, dd, $J_1 = 7.6$ Hz, $J_2 = 16.4$ Hz), 2.38 (3H, s); ¹³C NMR (CDCl₃) δ 156.3, 145.6, 140.4, 135.3, 134.5, 130.4, 129.9, 129.4, 126.6, 126.5, 121.5, 120.2, 118.6, 80.8, 40.9, 21.4; MS *m*/*z* 203 (100), 364 (M⁺); IR ν_{max} (cm⁻¹) 3133, 2920, 2852, 1634, 1597, 1504, 1042, 905, 841, 823. Anal. Calcd for C₂₀H₁₇ClN₄O: C, 65.84; H, 4.70; N, 15.36. Found: C, 65.75; H, 4.77; N, 15.28.

6f: pale yellow solid, mp 81–83 °C. ¹H NMR (CDCl₃) δ 7.94 (1H, s), 7.73 (2H, d, J = 8.0 Hz), 7.61–7.45 (5H, m), 7.39 (2H, d, J = 8.0 Hz), 6.79 (2H, s), 3.41 (1H, d, J = 16.4 Hz), 3.26 (1H, d, J = 16.4 Hz), 1.71 (3H, s); ¹³C NMR (CDCl₃) δ 155.3, 145.4, 136.8, 135.9, 134.3, 129.7, 128.9, 128.8, 128.3, 127.7, 120.4, 118.9, 116.8, 86.5, 46.4, 25.5; MS *m*/*z* 168 (100), 364 (M⁺); IR ν_{max} (cm⁻¹) 3126, 2924, 2850, 1632, 1599, 1500, 1088, 905, 759, 689, 540. Anal. Calcd for C₂₀H₁₇ClN₄O: C, 65.84; H, 4.70; N, 15.36. Found: C, 65.99; H, 4.62; N, 15.47.

6g: pale yellow solid, mp 91–92 °C. ¹H NMR (CDCl₃) δ 7.89 (1H, s), 7.71 (2H, d, J = 8.0 Hz), 7.55–7.44 (5H, m), 7.20 (2H, d, J = 8.0 Hz), 6.80 (1H, d, J = 15.6 Hz), 6.74 (1H, d, J = 15.6 Hz), 3.40 (1H, d, J = 16.4 Hz), 3.25 (1H, d, J = 16.4 Hz), 2.37 (3H, s), 1.71 (3H, s); ¹³C NMR (CDCl₃) δ 156.3, 145.6, 140.2, 136.8, 134.6, 129.7, 129.3, 128.7, 126.9, 126.4, 120.4, 118.7, 116.8, 85.9, 46.6, 25.4, 21.4; MS m/z 168 (100), 344 (M⁺); IR ν_{max} (cm⁻¹) 3125, 2922, 2852, 1633, 1598, 1502, 1355, 1231, 1074, 907, 758, 687, 537. Anal. Calcd for C₂₁H₂₀N₄O: C, 73.23; H, 5.85; N, 16.27. Found: C, 73.35; H, 5.94; N, 16.19.

Typical Procedure for the Preparation of Isoxazolyland Isoxazolinyl-Substituted Olefins (Products 10a-f). To a suspension of the swollen resin 7 (0.5 g) in anhydrous THF (15 mL), cooled to -60 °C, was added dropwise LDA (2 M in THF/hexane, 0.3 mL) under nitrogen. After stirring at -60 °C for 1.5 h, a solution of substituted allyl bromide (2 mmol) in anhydrous THF (1 mL) was added. The suspension was stirred for another 0.5 h at -60 °C, being slowly warmed to -40 °C over 0.5 h before quenching with H₂O (1 mL). Resin **8** was collected by filtration, washed with THF (10 mL \times 2), THF/H₂O (3:1) (10 mL \times 2), H₂O (10 mL \times 2), THF (10 mL \times 2), and CH₂Cl₂ (10 mL \times 2), and dried in a vacuum.

To a suspension of the swollen resin **8** (0.5 g) in CH₂Cl₂ (15 mL) was added a solution of hydroximoyl halide (1.5 mmol) in CH₂Cl₂ (10 mL) (prepared from 1.5 mmol of aldoxime and 1.5 mmol of NCS stirring at room temperature for 3 h before use). A solution of Et₃N (3 mmol) in CH₂Cl₂ (15 mL) was slowly added dropwise in three portions every 8 h (each time 1 mmol Et₃N, in 5 mL of anhydrous CH₂Cl₂ was added). After stirring for 24 h at room temperature, Resin **9** was collected by filtration, washed with THF (10 mL × 2), ether (10 mL × 2), THF/H₂O (3:1) (10 mL × 2), H₂O (10 mL × 2), THF (10 mL × 2), benzene (10 mL × 2), MeOH (10 mL × 2), and CH₂Cl₂ (10 mL × 2), and dried in a vacuum. The washed resin **9** was suspended in THF (15

mL), 30% (aq) H_2O_2 (0.5 mL) was added, and the mixture was stirred for 1 h at 0 °C followed by 20 min at room temperature. The mixture was filtered, and the resin was washed with CH₂Cl₂ (15 mL × 2). The filtrate was washed with H₂O (30 mL × 2), dried over MgSO₄, and evaporated to dryness under vacuum to obtain the crude products **10**. Further purification was via flash chromatography with *n*-hexanes—EtOAc (4:1 V/V) as the eluent for ¹³C NMR and microanalyses.

10a: pale yellow solid, mp 136–138 °C. ¹H NMR (CDCl₃) δ 7.69 (2H, d, J = 8.4 Hz), 7.45–7.34 (7H, m), 6.80 (1H, d, J = 16.0 Hz), 6.58 (1H, d, J = 16.0 Hz), 6.45 (1H, s), 4.32 (2H, q, J = 7.2 Hz), 3.61 (2H, d, J = 3.6 Hz), 1.36 (3H, t, J = 7.2 Hz); ¹³C NMR (CDCl₃) δ 167.5, 161.8, 160.2, 151.2, 140.4, 136.7, 136.1, 129.2, 128.9, 128.5, 128.0, 127.2, 125.4, 115.9, 100.7, 92.0, 62.2, 46.2, 14.1; MS *m*/*z* 282 (100), 422 (M⁺); IR ν_{max} (cm⁻¹) 2933, 1716, 1602, 1560, 1428, 1271, 1127, 1093, 930, 833, 767, 699. Anal. Calcd for C₂₃H₁₉-ClN₂O₄: C, 65.33; H, 4.53; N, 6.62. Found: C, 65.37; H, 4.58; N, 6.56.

10b: pale yellow solid, mp 118–119 °C. ¹H NMR (CDCl₃) δ 7.69 (2H, d, J = 8.0 Hz), 7.49–7.38 (5H, m), 7.27 (2H, d, J = 8.0 Hz), 6.83 (1H, d, J = 15.6 Hz), 6.61 (1H, d, J = 15.6 Hz), 6.49 (1H, s), 4.37 (2H, q, J = 7.2 Hz), 3.65 (2H, s), 2.41 (3H, s), 1.39 (3H, t, J = 7.2 Hz); ¹³C NMR (CDCl₃) δ 167.1, 162.8, 160.3, 151.3, 140.6, 140.3, 136.3, 129.7, 129.0, 128.6, 126.7, 126.0, 125.6, 115.9, 101.0, 92.2, 62.4, 46.2, 21.5, 14.2; MS m/z 282 (100), 402 (M⁺); IR ν_{max} (cm⁻¹) 2924, 1718, 1601, 1560, 1366, 1093, 928, 828, 761, 697. Anal. Calcd for C₂₄H₂₂N₂O₄: C, 71.63; H, 5.51; N, 6.96. Found: C, 71.71; H, 5.58; N, 7.03.

10c: pale yellow solid, mp 148–149 °C. ¹H NMR (CDCl₃) δ 7.68 (2H, d, J = 8.0 Hz), 7.63 (2H, d, J = 8.0 Hz), 7.55 (2H, d, J = 7.6 Hz), 7.45–7.37 (5H, m), 7.26 (2H, d, J = 7.6 Hz), 6.91 (1H, d, J = 16.0 Hz), 6.68 (1H, d, J = 16.0 Hz), 6.48 (1H, s), 3.76 (2H, s), 2.41 (3H, s); ¹³C NMR (CDCl₃) δ 167.4, 162.8, 155.4, 141.6, 140.3, 137.4, 136.4, 129.7, 129.1, 128.9, 128.3, 128.0, 127.8, 126.7, 126.1, 125.7, 115.6, 100.7, 89.8, 47.7, 21.4; MS *m*/*z* 199 (100), 440 (M⁺); IR ν_{max} (cm⁻¹) 2933, 1723, 1671, 1591, 1542, 1410, 1333, 1258, 977, 931, 841, 751. Anal. Calcd for C₂₇H₂₁ClN₂O₂: C, 73.55; H, 4.80; N, 6.35. Found: C, 73.48; H, 4.73; N, 6.26.

10d: pale yellow solid, mp 146–147 °C. ¹H NMR (CDCl₃) δ 7.71 (2H, d, J = 8.4 Hz), 7.57 (2H, d, J = 8.0 Hz), 7.54 (2H, d, J = 8.4 Hz), 7.44–7.40 (5H, m), 7.21 (2H, d, J = 8.0 Hz), 6.91 (1H, d, J = 15.8 Hz), 6.68 (1H, d, J = 15.8 Hz), 6.44 (1H, s), 3.75 (2H, d, J = 2.2 Hz), 2.37 (3H, s); ¹³C NMR (CDCl₃) δ 167.9, 161.7, 156.2, 141.5, 140.7, 138.0, 136.0, 129.4, 129.1, 128.7, 128.1, 128.0, 127.3, 126.6, 126.2, 125.6, 114.9, 100.3, 89.1, 47.8, 21.4; MS *m*/*z* 199(100), 440 (M⁺); IR ν_{max} (cm⁻¹) 2933, 1723, 1671, 1591, 1542, 1410, 1333, 1258, 977, 931, 841, 751. Anal. Calcd for C₂₇H₂₁-ClN₂O₂: C, 73.55; H, 4.80; N, 6.35. Found: C, 73.48; H, 4.73; N, 6.26.

10e: pale yellow solid, mp 172–173 °C. ¹H NMR (CDCl₃) δ 7.68–7.65 (4H, m), 7.53 (2H, d, J = 7.6 Hz), 7.44–7.34 (3H, m), 7.35 (2H, d, J = 7.6 Hz), 7.10 (2H, t, J = 8.6 Hz), 6.89 (1H, d, J = 15.8 Hz), 6.66 (1H, d, J = 15.8 Hz), 6.45

(1H, s), 3.74 (2H, s), 2.38 (3H, s); ¹³C NMR (CDCl₃) δ 167.3, 163.9 (J = 248.8 Hz), 162.7, 155.3, 141.5, 140.2, 137.4, 129.5, 128.8, 128.7 (J = 8.3 Hz), 128.2, 126.6, 126.0, 125.6, 125.5 (J = 3.6 Hz), 115.9 (J = 21.9 Hz), 115.4, 100.6, 89.5, 47.8, 21.4; MS m/z 199 (100), 424 (M⁺); IR ν_{max} (cm⁻¹) 2933, 1723, 1671, 1591, 1542, 1410, 1333, 1258, 977, 931, 841, 751. Anal. Calcd for C₂₇H₂₁FN₂O₂: C, 76.40; H, 4.99; N, 6.60. Found: C, 76.28; H, 5.03; N, 6.66.

10f: pale yellow solid, mp 174–176 °C. ¹H NMR (CDCl₃) δ 7.72–7.70 (4H, m), 7.54 (2H, d, J = 7.6 Hz), 7.44–7.33 (5H, m), 7.10 (2H, t, J = 8.4 Hz), 6.90 (1H, d, J = 15.8 Hz), 6.67 (1H, d, J = 15.8 Hz), 6.45 (1H, s), 3.75 (2H, d, J = 3.0 Hz); ¹³C NMR (CDCl₃) δ 167.9, 164.0 (J = 250.1 Hz), 161.8, 155.3, 141.5, 137.9, 136.1, 129.2, 128.9, 128.7 (J = 9.1 Hz), 128.3, 128.0, 127.4, 125.6, 125.5 (J = 3.7 Hz), 116.0 (J = 22.0 Hz), 115.2, 100.4, 89.5, 47.8; MS m/z 199(100), 444 (M⁺); IR ν_{max} (cm⁻¹) 2933, 1723, 1671, 1591, 1542, 1410, 1333, 1258, 977, 931, 841, 751. Anal. Calcd for C₂₆H₁₈ClFN₂O₂: C, 70.19; H, 4.08; N, 6.30. Found: C, 70.28; H, 4.03; N, 6.26.

General Procedure for the Preparation of Polystyrene-Supported α -Selenoacetic Acids 11. To a THF/DMF (v/v 3/1) (20 mL) swollen polystyrene-supported selenenyl bromide 1, NaBH₄ (2 mmol) was added and stirred at 40 °C for 6 h. Cooled to 0 °C, bromoacetic acid (3 mmol) in THF (2 mL) was added slowly, and the mixture was stirred for another 2 h at room temperature. The resin was collected by filtration and washed successively with THF (10 mL × 2), THF/H₂O (3:1) (10 mL × 2), 0.1 N HCl solution (10 mL), H₂O (10 mL × 2), THF (10 mL × 2), and CH₂Cl₂ (10 mL × 2), and then dried in a vacuum overnight to afford resin 11.

Typical Procedure for the Preparation of Polystyrene-Supported Oxadiazolyl-Substituted Selenium Resin 12. To a suspension of the swollen polystyrene-supported α -selenoacetic acid resin 11 (1.0 g) in anhydrous 1,4-dioxane (15 mL) was added DCC (4.0 mmol) and amidoxime (2.5 mmol) under nitrogen. The mixture was stirred at 95 °C for 20 h. Resin 12 was collected by filtration, washed with hot THF (10 mL × 2) and hot EtOH (10 mL × 2), and dried in a vacuum.

Typical Procedure for the Preparation of Oxadiazolyland Isoxazolinyl-Substituted Olefins (Products 15a–s). To a suspension of the swollen resin 12 (0.5 g) in anhydrous THF (15 mL), cooled to -60 °C, was added dropwise LDA (2 M in THF/hexane, 0.3 mL) under nitrogen. After stirring for 1.5 h at -60 °C, a solution of allyl bromide (2 mmol) in anhydrous THF (1 mL) was added. The suspension was stirred for another 0.5 h at -60 °C, being slowly warmed to -40 °C over 0.5 h before quenching with H₂O (1 mL). Resin 13 was collected by filtration, washed with THF (10 mL × 2), THF/H₂O (3:1) (10 mL × 2), H₂O (10 mL × 2), THF (10 mL × 2), and CH₂Cl₂ (10 mL × 2), and dried under vacuum.

To the suspension of the swollen resin **13** (0.5 g) in CH_2Cl_2 (15 mL) was added a solution of hydroximoyl halide (4.0 mmol) in CH_2Cl_2 (10 mL) (prepared from 4.0 mmol of aldoxime and 4.0 mmol of NCS stirring at room temperature for 3 h before use). A solution of Et_3N (5 mmol) in CH_2Cl_2

(15 mL) was added dropwise in three portions every 8 h (each time 1.66 mmol in anhydrous CH₂Cl₂ (5 mL) was added). After stirring for 24 h at room temperature, resin 14 was collected by filtration, washed with THF (10 mL \times 2), ether (10 mL \times 2), THF/H₂O (3:1) (10 mL \times 2), H₂O (10 mL \times 2), THF (10 mL \times 2), benzene (10 mL \times 2), MeOH (10 mL \times 2), and CH₂Cl₂ (10 mL \times 2), and dried in a vacuum. The washed resin 14 was suspended in THF (15 mL), 30% (aq) H₂O₂ (0.5 mL) was added, and the mixture was stirred at 0 °C for 1 h followed by 20 min at room temperature. The mixture was filtered, and the resin was washed with CH_2Cl_2 (15 mL \times 2). The filtrate was washed with H_2O (30 mL \times 2), dried over MgSO₄, and evaporated to dryness under vacuum to obtain the crude products 15. Further purification was via flash chromatography with *n*-hexanes–EtOAc (4:1 v/v) as the eluent for ${}^{13}C$ NMR and microanalyses.

15a: pale yellow solid, mp 138–140 °C. ¹H NMR (CDCl₃) δ 7.96 (2H, d, J = 8.0 Hz), 7.61 (2H, d, J = 8.4 Hz), 7.39 (2H, d, J = 8.4 Hz), 7.28 (2H, d, J = 8.0 Hz), 7.12 (1H, dd, $J_1 = 5.6$ Hz, $J_2 = 16.0$ Hz), 6.83 (1H, d, J = 16.0 Hz), 5.47– 5.44 (1H, m), 3.65 (1H, dd, $J_1 = 10.4$ Hz, $J_2 = 16.4$ Hz), 3.25 (1H, dd, $J_1 = 7.2$ Hz, $J_2 = 16.4$ Hz), 2.41 (3H, s); ¹³C NMR (CDCl₃) δ 173.7, 168.7, 155.2, 141.9, 141.6, 136.5, 129.6, 129.1, 128.0, 127.4, 127.3, 123.8, 115.0, 79.6, 40.6, 21.5; MS m/z 132 (100), 365 (M⁺); IR ν_{max} (cm⁻¹) 3032, 2918, 1671, 1615, 1546, 1353, 1091, 905, 828, 750, 509. Anal. Calcd for C₂₀H₁₆ClN₃O₂: C, 65.67; H, 4.41; N, 11.49. Found: C, 65.77; H, 4.36; N, 11.55.

15b: pale yellow solid, mp 94–95 °C. ¹H NMR (CDCl₃) δ 8.08–8.04 (2H, m), 7.61 (2H, d, J = 8.0 Hz), 7.54 (2H, d, J = 8.0 Hz), 7.45–7.30 (6H, m), 7.15 (2H, t, J = 8.6 Hz), 6.79 (1H, d, J = 16.0 Hz), 3.77 (2H, d, J = 4.0 Hz); ¹³C NMR (CDCl₃) δ 174.2, 167.9, 164.6 (J = 250.5 Hz), 15.2, 145.8, 140.5, 136.5, 129.5 (J = 8.7 Hz), 129.1, 129.0, 128.5, 127.9, 127.5, 125.5, 122.9 (J = 3.2 Hz), 116.0 (J = 22.0 Hz), 113.1, 89.4, 47.2; MS m/z 128 (100), 445 (M⁺); IR $\nu_{\rm max}$ (cm⁻¹) 3028, 2924, 1662, 1596, 1410, 917, 830, 751, 695. Anal. Calcd for C₂₅H₁₇FClN₃O₂: C, 67.34; H, 3.84; N, 9.42. Found: C, 67.41; H, 3.91; N, 9.38.

15c: pale yellow solid, mp 77–78 °C. ¹H NMR (CDCl₃) δ 7.97 (2H, d, J = 8.0 Hz), 7.29 (2H, d, J = 8.0 Hz), 7.06 (1H, dd, $J_1 = 5.6$ Hz, $J_2 = 16.0$ Hz), 6.77 (1H, d, J = 16.0 Hz), 5.51–5.48 (1H, m), 4.37 (2H, q, J = 7.2 Hz), 3.54 (1H, dd, $J_1 = 11.6$ Hz, $J_2 = 17.6$ Hz), 3.17 (1H, dd, $J_1 = 7.6$ Hz, $J_2 = 17.6$ Hz), 2.41 (3H, s), 1.38 (3H, t, J = 7.2 Hz); ¹³C NMR (CDCl₃) δ 173.4, 168.8, 160.1, 151.2, 141.7, 140.6, 129.6, 127.3, 123.7, 115.4, 81.5, 62.4, 39.3, 21.6, 14.1; MS m/z 132 (100), 327 (M⁺); IR ν_{max} (cm⁻¹) 2928, 1738, 1668, 1615, 1596, 1547, 1240, 920, 827, 749, 506. Anal. Calcd for C₁₇H₁₇N₃O₄: C, 62.38; H, 5.23; N, 12.84. Found: C, 62.31; H, 5.18; N, 12.90.

15d: pale yellow solid, mp 103–104 °C. ¹H NMR (CDCl₃) δ 7.95 (2H, d, J = 8.0 Hz), 7.48–7.28 (8H, m), 6.72 (1H, d, J = 16.0 Hz), 4.35 (2H, q, J = 7.2 Hz), 3.67 (2H, d, J = 2.0 Hz), 2.41 (3H, s), 1.37 (3H, t, J = 7.2 Hz); ¹³C NMR (CDCl₃) δ 173.7, 168.8, 160.1, 151.2, 144.4, 141.6, 139.6, 129.6, 129.1, 128.8, 127.3, 125.4, 123.8, 113.6, 91.7, 62.4, 45.9, 21.5, 14.1; MS m/z 84 (100), 404 (M⁺ + 1); IR ν_{max} (cm⁻¹)

3028, 2983, 1713, 1672, 1592, 1557, 1271, 936, 831, 748, 704. Anal. Calcd for $C_{23}H_{21}N_3O_4$: C, 68.47; H, 5.25; N, 10.42. Found: C, 68.56; H5.18; N, 10.51.

15e: pale yellow solid, mp 141–142 °C. ¹H NMR (CDCl₃) δ 7.95 (2H, d, J = 8.0 Hz), 7.54–7.28 (12H, m), 6.78 (1H, d, J = 16.0 Hz), 3.77 (2H, d, J = 2.8 Hz), 2.40 (3H, s); ¹³C NMR (CDCl₃) δ 174.0, 168.7, 155.3, 145.5, 141.6, 140.5, 132.0, 129.5, 129.0, 128.5, 128.1, 128.0, 127.3, 125.6, 124.9, 123.8, 113.3, 89.5, 47.1, 21.5; MS *m*/*z* 128 (100), 485 (M⁺), 487 (M⁺ + 2); IR ν_{max} (cm⁻¹) 3025, 2977, 1661, 1595, 1555, 1360, 910, 830, 751, 697. Anal. Calcd for C₂₆H₂₀BrN₃O₂: C, 64.21; H, 4.14; N, 8.64. Found: C, 64.33; H, 4.07; N, 8.55.

15f: pale yellow solid, mp 137–179 °C. ¹H NMR (CDCl₃) δ 7.94 (2H, d, J = 8.0 Hz), 7.60 (2H, d, J = 8.4 Hz), 7.54–7.33 (8H, m), 7.25 (2H, d, J = 8.0 Hz), 6.78 (1H, d, J = 16.0 Hz), 3.76 (2H, d, J = 2.0 Hz), 2.39 (3H, s); ¹³C NMR (CDCl₃) δ 174.0, 168.7, 155.3, 145.6, 141.6, 140.6, 136.5, 129.6, 129.1, 129.0, 128.5, 127.9, 127.6, 125.6, 124.9, 123.9, 113.3, 89.5, 47.1, 21.5; MS *m*/*z* 128 (100), 442 (M⁺ + 1); IR ν_{max} (cm⁻¹) 3025, 1662, 1595, 1557, 1406, 1360, 1093, 910, 828, 748, 699, 553. Anal. Calcd for C₂₆H₂₀ClN₃O₂: C, 70.67; H, 4.56; N, 9.51. Found: C, 70.77; H, 4.67; N, 9.42.

15g: low point solid. ¹H NMR (CDCl₃) δ 7.94 (2H, d, J = 8.0 Hz), 7.56–7.52 (4H, m), 7.43–7.33 (4H, m), 7.25 (2H, d, J = 8.4 Hz), 7.19 (2H, d, J = 8.0 Hz), 6.78 (1H, d, J = 16.0 Hz), 3.77 (2H, s), 2.38 (3H, s), 2.34 (3H, s); ¹³C NMR (CDCl₃) δ 174.1, 168.7, 156.1, 145.9, 141.5, 140.9, 140.8, 129.6, 129.5, 128.9, 128.3, 127.3, 126.7, 126.2, 125.6, 123.9, 113.1, 88.9, 47.4, 21.5, 21.4; MS *m*/*z* 128 (100), 421 (M⁺); IR ν_{max} (cm⁻¹) 3025, 1662, 1595, 1557, 1409, 1366, 911, 830, 756, 698. Anal. Calcd for C₂₇H₂₃N₃O₂: C, 76.94; H, 5.50; N, 9.97. Found: C, 76.85; H, 5.42; N, 10.06.

15h: pale yellow solid, mp 92–94 °C. ¹H NMR (CDCl₃) δ 8.08–8.05 (2H, m), 7.48–7.38 (5H, m), 7.32 (1H, d, J = 16.0 Hz), 7.16 (2H, t, J = 8.8 Hz), 6.72 (1H, d, J = 16.0 Hz), 4.36 (2H, q, J = 7.2 Hz), 3.67 (2H, d, J = 3.6 Hz), 1.37 (3H, t, J = 7.2 Hz); ¹³C NMR (CDCl₃) δ 174.0, 167.9, 164.6 (J = 250.4 Hz), 160.0, 151.1, 144.7, 139.6, 129.5 (J = 9.2 Hz), 129.1, 128.8, 125.4, 122.8 (J = 3.8 Hz), 116.0 (J = 21.9 Hz), 113.4, 91.6, 62.4, 45.9, 14.1; MS *m*/*z* 128 (100), 407 (M⁺); IR ν_{max} (cm⁻¹) 3025, 2983, 1721, 1660, 1601, 1547, 1410, 1270, 973, 833, 748, 698, 627. Anal. Calcd for C₂₂H₁₈FN₃O₄: C, 64.86; H, 4.45; N, 10.31. Found: C, 64.91; H, 4.37; N, 10.38.

15i: low point solid. ¹H NMR (CDCl₃) δ 8.08 (2H, d, J = 7.6 Hz), 7.51–7.47 (3H, m), 7.07 (1H, dd, $J_1 =$ 5.6 Hz, $J_2 =$ 16.0 Hz), 6.78 (1H, d, J = 16.0 Hz), 5.53–5.47 (1H, m), 4.37 (2H, q, J = 7.2 Hz), 3.54 (1H, dd, $J_1 =$ 11.6 Hz, $J_2 =$ 17.6 Hz), 3.17 (1H, dd, $J_1 =$ 7.6 Hz, $J_2 =$ 17.6 Hz), 1.38 (3H, t, J = 7.2 Hz); ¹³C NMR (CDCl₃) δ 173.6, 168.7, 160.0, 151.2, 140.7, 131.3, 128.9, 127.4, 126.6, 115.4, 81.4, 62.4, 39.4, 14.1; MS *m*/*z* 119 (100), 313 (M⁺); IR ν_{max} (cm⁻¹) 3029, 2924, 1735, 1666, 1596, 1580, 1410, 1240, 920, 827, 758, 691, 542. Anal. Calcd for C₁₆H₁₅N₃O₄: C, 61.34; H, 4.83; N, 13.41. Found: C, 61.27; H, 4.77; N, 13.47.

15j: pale yellow solid, mp 132–133 °C. ¹H NMR (CDCl₃) δ 8.09–8.06 (2H, m), 7.60 (2H, d, J = 8.0 Hz), 7.51–7.48 (3H, m), 7.39 (2H, d, J = 8.0 Hz), 7.14 (1H, dd, $J_1 = 5.6$

Hz, $J_2 = 16.0$ Hz), 6.83 (1H, d, J = 16.0 Hz), 5.49–5.43 (1H, m), 3.65 (1H, dd, $J_1 = 10.4$ Hz, $J_2 = 16.4$ Hz), 3.25 (1H, dd, $J_1 = 7.2$ Hz, $J_2 = 16.4$ Hz); ¹³C NMR (CDCl₃) δ 173.9, 168.8, 155.2, 142.0, 136.5, 131.2, 131.2, 129.1, 129.9, 128.0, 127.4, 126.6, 114.9, 79.5, 40.6; MS m/z 55 (100), 351 (M⁺); IR ν_{max} (cm⁻¹) 2924, 1670, 1595, 1549, 1360, 1093, 976, 889, 828, 732, 693. Anal. Calcd for C₁₉H₁₄-ClN₃O₂: C, 64.87; H, 4.01; N, 11.94. Found: C, 64.95; H, 4.07; N, 11.87.

15k: pale yellow solid, mp 128 °C. ¹H NMR (CDCl₃) δ 8.09–8.06 (2H, m), 7.56 (2H, d, J = 8.0 Hz), 7.50–7.47 (3H, m), 7.22 (2H, d, J = 8.0 Hz), 7.14 (1H, dd, $J_1 = 5.6$ Hz, $J_2 = 16.0$ Hz), 6.83 (1H, d, J = 16.0 Hz), 5.49–5.43 (1H, m), 3.66 (1H, dd, $J_1 = 10.8$ Hz, $J_2 = 16.4$ Hz), 3.27 (1H, dd, $J_1 = 7.2$ Hz, $J_2 = 16.4$ Hz), 2.38 (3H, s); ¹³C NMR (CDCl₃) δ 174.0, 168.7, 156.1, 142.4, 140.8, 131.2, 129.5, 128.8, 127.4, 126.7, 126.1, 114.7, 79.1, 40.8, 21.4; MS *m*/*z* 91(100), 331 (M⁺); IR ν_{max} (cm⁻¹) 2920, 1668, 1548, 1445, 1360, 978, 904, 823, 735, 693, 542. Anal. Calcd for C₂₀H₁₇N₃O₂: C, 72.49; H, 5.17; N, 12.68. Found: C, 72.61; H, 5.11; N, 12.79.

151: pale yellow solid, mp 111–112 °C. ¹H NMR (CDCl₃) δ 8.09–8.06 (2H, m), 7.61 (2H, d, J = 7.2 Hz), 7.50–7.47 (3H, m), 7.14 (1H, dd, $J_1 = 5.6$ Hz, $J_2 = 16.0$ Hz), 6.92 (2H, d, J = 7.2 Hz), 6.83 (1H, d, J = 16.0 Hz), 5.42–5.39 (1H, m), 3.84 (3H, s), 3.65 (1H, dd, $J_1 = 10.8$ Hz, $J_2 = 16.4$ Hz), 3.27 (1H, dd, $J_1 = 7.2$ Hz, $J_2 = 16.4$ Hz); ¹³C NMR (CDCl₃) δ 174.0, 168.7, 161.4, 155.7, 142.6, 131.2, 128.8, 128.3, 127.4, 126.7, 121.4, 114.7, 114.2, 79.1, 55.4, 40.9; MS m/z 347 (100, M⁺); IR ν_{max} (cm⁻¹) 2920, 1669, 1607, 1545, 1364, 1253, 1179, 976, 835, 733, 695. Anal. Calcd for C₂₀H₁₇N₃O₃: C, 69.15; H, 4.93; N, 12.10. Found: C, 69.05; H, 4.99; N, 12.01.

15m: low point solid. ¹H NMR (CDCl₃) δ 7.99 (2H, d, J = 8.4 Hz), 7.57–7.53 (4H, m), 7.44–7.35 (6H, m), 7.20 (2H, d, J = 8.0 Hz), 6.78 (1H, d, J = 15.8 Hz), 3.78 (2H, d, J = 2.8 Hz), 2.37 (3H, s); ¹³C NMR (CDCl₃) δ 174.5, 167.9, 156.1, 146.3, 140.9, 140.8, 137.4, 129.5, 129.2, 128.9, 128.7, 128.4, 126.7, 126.1, 125.6, 125.2, 112.9, 88.9, 47.5, 21.4; MS m/z 128 (100), 441 (M⁺); IR ν_{max} (cm⁻¹) 3028, 2928, 1664, 1597, 1558, 1410, 1360, 911, 828, 749, 697, 554. Anal. Calcd for C₂₆H₂₀ClN₃O₂: C, 70.67; H, 4.56; N, 9.51. Found: C, 70.78; H, 4.47; N, 9.59.

15n: pale yellow solid, mp 160–161 °C. ¹H NMR (CDCl₃) δ 8.02 (2H, d, J = 6.8 Hz), 7.61 (2H, d, J = 6.8 Hz), 7.46 (2H, d, J = 6.8 Hz), 7.40 (2H, d, J = 6.8 Hz), 7.14 (1H, dd, $J_1 = 5.6$ Hz, $J_2 = 16.0$ Hz), 6.83 (1H, d, J = 16.0 Hz), 5.50– 5.45 (1H, m), 3.66 (1H, dd, $J_1 = 10.8$ Hz, $J_2 = 16.4$ Hz), 3.25 (1H, dd, $J_1 = 7.2$ Hz, $J_2 = 16.4$ Hz); ¹³C NMR (CDCl₃) δ 174.1, 168.0, 155.2, 142.3, 137.4, 136.6, 129.2, 129.1, 128.7, 128.0, 127.4, 125.2, 114.8, 79.5, 40.6; MS m/z 55 (100), 385 (M⁺); IR ν_{max} (cm⁻¹) 3028, 2925, 1671, 1615, 1546, 1403, 905, 828, 746, 510. Anal. Calcd for C₁₉H₁₃-Cl₂N₃O₂: C, 59.08; H, 3.39; N, 10.88. Found: C, 58.97; H, 3.31; N, 10.99.

150: pale yellow solid, mp 120–122 °C. ¹H NMR (CDCl₃) δ 8.00 (2H, d, J = 8.4 Hz), 7.53–7.35 (12H, m), 6.79 (1H, d, J = 16.0 Hz), 3.78 (2H, d, J = 5.2 Hz); ¹³C NMR (CDCl₃) δ 174.4, 167.9, 155.4, 145.9, 140.5, 137.4, 132.1, 129.2,

129.0, 128.7, 128.5, 128.1, 127.9, 125.5, 125.2, 124.9, 113.1, 89.4, 47.2; MS m/z 128 (100), 506 (M⁺), 506 (M⁺ + 2); IR $\nu_{\rm max}$ (cm⁻¹) 3025, 2924, 1665, 1595, 1557, 918, 829, 754, 695. Anal. Calcd for C₂₅H₁₇BrClN₃O₂: C, 59.25; H, 3.38; N, 8.29. Found: C, 59.38; H, 3.32; N, 8.40.

15p: pale yellow solid, mp 98–99 °C. ¹H NMR (CDCl₃) δ 8.02 (2H, d, J = 8.4 Hz), 7.46 (2H, d, J = 8.4 Hz), 7.07 (1H, dd, $J_1 = 5.6$ Hz, $J_2 = 16.0$ Hz), 6.78 (1H, d, J = 16.0 Hz), 5.53–5.49 (1H, m), 4.37 (2H, q, J = 7.2 Hz), 3.55 (1H, dd, $J_1 = 11.6$ Hz, $J_2 = 17.6$ Hz), 3.17 (1H, dd, $J_1 = 7.6$ Hz, $J_2 = 17.6$ Hz), 1.38 (3H, t, J = 7.2 Hz); ¹³C NMR (CDCl₃) δ 173.8, 168.0, 160.1, 151.2, 141.0, 137.5, 129.2, 128.7, 125.1, 115.2, 81.3, 62.4, 39.4, 14.1; MS *m*/*z* 199 (100), 347 (M⁺); IR ν_{max} (cm⁻¹) 2933, 1723, 1671, 1591, 1542, 1410, 1333, 1258, 977, 931, 841, 751. Anal. Calcd for C₁₆H₁₄-ClN₃O₄: C, 55.26; H, 4.06; N, 12.08. Found: C, 55.37; H, 4.13; N, 12.16.

15q: pale yellow solid, mp 148–150 °C. ¹H NMR (CDCl₃) δ 8.01 (2H, d, J = 8.4 Hz), 7.61 (2H, d, J = 8.8 Hz), 7.45 (2H, d, J = 8.4 Hz), 7.14 (1H, dd, $J_1 = 5.6$ Hz, $J_2 = 16.0$ Hz), 6.92 (2H, d, J = 8.8 Hz), 6.82 (1H, d, J = 16.0 Hz), 5.44–5.38 (1H, m), 3.84 (3H, s), 3.65 (1H, dd, $J_1 = 11.2$ Hz, $J_2 = 16.4$ Hz), 3.26 (1H, dd, $J_1 = 7.2$ Hz, $J_2 = 16.4$ Hz); ¹³C NMR (CDCl₃) δ 174.2, 167.9, 161.4, 155.7, 142.9, 137.4, 129.1, 128.7, 128.4, 125.2, 121.3, 114.5, 114.2, 79.0, 55.4, 40.9; MS m/z 149 (100), 381 (M⁺); IR ν_{max} (cm⁻¹) 2932, 1670, 1610, 1550, 1518, 1409, 1362, 1258, 1179, 1093, 973, 896, 832, 751, 540. Anal. Calcd for C₂₀H₁₆ClN₃O₃: C, 62.91; H, 4.22; N, 11.01. Found: C, 62.77; H, 4.17; N, 11.12.

15r: pale yellow solid, mp 129–130 °C. ¹H NMR (CDCl₃) δ 8.27 (2H, d, J = 8.6 Hz), 7.99 (2H, d, J = 8.0 Hz), 7.85 (2H, d, J = 8.6 Hz), 7.55–7.37 (8H, m), 6.79 (1H, d, J = 16.0 Hz), 3.84 (2H, d, J = 4.8 Hz); ¹³C NMR (CDCl₃) δ174.2, 167.9, 154.6, 148.7, 145.4, 140.1, 137.5, 135.0, 129.2, 129.1, 128.7, 128.6, 127.4, 125.5, 125.1, 124.1, 113.3, 90.3, 46.8; MS *m*/*z* 128 (100), 472 (M⁺); IR ν_{max} (cm⁻¹) 2930, 1675, 1611, 1518, 1409, 1350, 1093, 915, 824, 758, 699, 540. Anal. Calcd for C₁₉H₁₃ClN₄O₄: C, 57.51; H, 3.30; N, 14.12. Found: C, 57.40; H, 3.22; N, 14.01.

15s: pale yellow solid, mp 119–121 °C. ¹H NMR (CDCl₃) δ 8.00 (2H, d, J = 8.4 Hz), 7.48–7.31 (8H, m), 6.73 (1H, d, J = 16.0 Hz), 4.36 (2H, q, J = 7.2 Hz), 3.68 (2H, d, J = 4.4 Hz), 1.37 (3H, t, J = 7.2 Hz); ¹³C NMR (CDCl₃) δ 174.1, 160.0, 151.1, 144.8, 139.6, 137.4, 129.2, 129.0, 128.8, 128.7, 125.4, 125.1, 113.4, 91.6, 62.4, 45.9; MS m/z 128 (100), 423 (M⁺); IR ν_{max} (cm⁻¹) 3078, 2982, 1722, 1660, 1602, 1545, 1409, 1351, 1271, 1251, 1126, 971, 933, 836, 748, 696, 616. Anal. Calcd for C₂₂H₁₈ClN₃O₄: C, 62.34; H, 4.28; N, 9.91. Found: C, 62.47; H, 4.37; N, 9.83.

Acknowledgment. We are grateful to the National Natural Science Foundation of China (project no. 20332050).

Supporting Information Available. ¹H NMR and ¹³C NMR spectra of all the products and parts and HPLC spectra of **6a**, **6g**, **10a**, **10i**, **15d**, **15n**. This material is available free of charge via the Internet at http://pubs.acs.org.

References and Notes

- (a) Guilliier, F.; Orain, D.; Bradley, M. Chem. Rev. 2000, 100, 2091–2157. (b) James, I. W. Tetrahedron 1999, 55, 4855–4946. (c) Sammelson, R. E.; Kurth, M. J. Chem. Rev. 2001, 137–202. (d) Czarnik, A. W. Solid-Phase Organic Synthesis; Wiley: New York, 2001; Vol. 1. (e) Nicolaou, K. C.; Hanko, R.; Hartwig, W. Handbook of Combinatorial Chemistry; Wiley-VCH: Weinheim, 2002.
- (2) (a) Franzen, R. G. J. Comb. Chem. 2000, 2, 195–214. (b) Dowald, F. Z. Organic Synthesis on Solid Phase; Wiley-VCH: Weinheim, 2002; Chapter 15.
- (3) (a) Rowley, M.; Broughton, H. B.; Collins, I.; Baker, R.; Emms, F.; Marwood, R.; Patel, S.; Patel, S.; Ragan, C. I.; Freedman, S. B.; Leeson, P. D. J. Med. Chem. 1996, 39, 1943–1945. (b) Simoni, D.; Roberti, M.; Invidiata, F. P.; Rondanin, R.; Baruchello, R.; Malagutti, C.; Mazzali, A.; Rossi, M.; Grimaudo, S.; Capone, F.; Dusonchet, L.; Meli, M.; Raimondi, M. V.; Landino, M.; D'Allesandro, N.; Tolomeo, M.; Arindam, D.; Lu, S.; Benbrook, D. M. J. Med. Chem. 2001, 44, 2308–2318. (c) Wityak, J.; Sielecki, T. M.; Pinto, D. J.; Emmett, G.; Sze, J. Y.; Liu, J.; Tobin, A. E.; Wang, S.; Jiang, B.; Ma, P.; Mousa, S. A.; Olson, R. E.; Wexler, R. R. J. Med. Chem. 1997, 40, 50–60.
- (4) (a) Macor, J. E.; Ordway, T.; Smith, R. L.; Verhoest, P. R.; Mack, R. A. J. Org. Chem. 1996, 61, 3228–3229. (b) Street, L. J.; Baker, R.; Book, T.; Kneen, C. O.; MacLeod, A. M.; Merchant, K. J.; Showell, G. A.; Saunders, J.; Herbert, R. H.; Freedman, S. B.; Harley, E. A. J. Med. Chem. 1990, 33, 2690–2697. (c) Tully, W. R.; Gardner, C. R.; Illespie, R. J.; Westwood, R. J. Med. Chem. 1991, 34, 2060–2067. (d) Diana, G. D.; Volkots, D. L.; Nitz, T. J.; Bailey, T. R.; Long, M. A.; Niranjan, V.; Aldous, S.; Pevear, D. C.; Dutko, F. J. J. Med. Chem. 1994, 37, 2421–2436.
- (5) (a) Buckle, D. R.; Rockell, C. J. M.; Smith, H.; Spicer, B. A. J. Med. Chem. 1986, 29, 2269–2267. (b) Genin, M. J.; Allwine, D. A.; Anderson, D. J.; Barbachyn, M. R.; Emmert, D. E.; Garmon, S. A.; Graber, D. R.; Grega, K. C.; Hester, J. B.; Hutchinson, D. K.; Morris, J.; Reischer, R. J.; Ford, C. W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; Yagi, B. H. J. Med. Chem. 2000, 43, 953–970. (c) Alvarez, R.; Velazquez, S.; San-Felix, A.; Aquaro, S.; De Clercq, E.; Perno, C.-F.; Karlsson, A.; Balzarini, J.; Camarasa, M. J. J. Med. Chem. 1994, 37, 4185–4194.
- (6) (a) Dolle, R. E. J. Comb. Chem. 2004, 6, 623-679. (b) Kurth, M. J.; Kantorowski, E. J. J. Org. Chem. 1997, 62, 6797-6803. (c) Quan, C.; Kurth, M. J. J. Org. Chem. 2004, 69, 1470-1474. (d) Harju, K., Vahermo, M.; Mutikainen, I.; Yli-Kauhaluoma, J. J. Comb. Chem. 2003, 5, 826-833.
- (7) (a) Garanti, L.; Molteni, G. *Tetrahedron Lett.* 2003, 44, 1133–1135. (b) Blass, B. E.; Coburn, K. R.; Faulkner, A. L.; Hunn, C. L.; Natchus, M. G.; Parker, M. S.; Portlock,

D. E.; Tullis, J. S.; Wood R. *Tetrahedron Lett.* **2002**, *43*, 4059–4061. (c) Gouault, N.; Cupif, J.-F.; Sauleau, A.; David, M. *Tetrahedron Lett.* **2000**, *41*, 7293–7297. (d) Freeze, S.; Norris, P. *Heterocycles* **1999**, *51*, 1807–1817. (e) Tornøe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. **2002**, *67*, 3057–3064. (f) Moore, M.; Norris, P. *Tetrahedron Lett.* **1998**, *39*, 7027–7030. (g) Zaragoza, F.; Petersen, S. V. *Tetrahedron* **1996**, *52*, 10823–10826.

- (8) Scriven, E. F. V.; Turnbull, K. Chem. Rev. 1988, 2, 297– 368.
- (9) (a) Gonzalez, M. A.; Pattenden, G. Angew. Chem., Int. Ed. Engl. 2003, 42, 1255–1258.
- (10) Huang, X.; Xu, W. M. Org. Lett. 2003, 5, 4649-4652.
- (11) Barrett, A. G. M.; Procopiou, P. A.; Voigtmann, U. Org. Lett. 2001, 3, 3165–3168.
- (12) Michels, R.; Kato, M.; Heitz, W. Makromol. Chem. 1976, 177, 2311–2317.
- (13) Nicolaou, K. C.; Pastor, J.; Barluenga, S.; Winssinger, N. Chem. Commun. 1998, 1947–1948.
- (14) (a) Nicolaou, K. C.; Pfefferkorn, J. A.; Roecker, A. J.; Cao, G. Q.; Barluenga, S.; Mitchell, H. J. J. Am. Chem. Soc. 2000, 122, 9939–9953. (b) Ruhland, T.; Andersen, K.; Pedersen, H. J. Org. Chem. 1998, 63, 9204–9211. (c) Zaragoza, F. Angew. Chem., Int. Ed. Engl. 2000, 39, 2077–2079. (d) Fujita, K.; Hashimoto, S.; Oishi, A.; Taguchi, Y. Tetrahedron Lett. 2003, 44, 3793–3795. (e) Cohen, R. J.; Fox, D. L.; Salvatore, R. N. J. Org. Chem. 2004, 69, 4265–4268.
- (15) (a) Huang, X.; Xu, W. M. *Tetrahedron Lett.* 2002, 43, 5495–5497. (b) Xu, W. M.; Tang, E.; Huang, X. *Synthesis* 2004, 2094–2099. (c) Tang, E.; Huang, X.; Xu, W. M. *Tetrahedron* 2004, 60, 9963–9969. (d) Huang, X.; Sheng, S. R. *J. Comb. Chem.* 2003, 5, 273–277. (e) Qian, H.; Huang, X. *J. Comb. Chem.* 2003, 5, 569–576.
- (16) (a) Zhu, W.; Ma, D. Chem. Commun. 2004, 7, 888–889.
 (b) Feldman, A. K.; Colasson, B.; Fokin, V. V. Org. Lett. 2004, 6, 3897–3899. (c) Kacprzak, K. Synlett 2005, 943–946.
- (17) (a) Padwa, A. 1,3-Dipolar Cycloaddition Chemistry; John Wiley & Sons: New York, 1984. (b) Torsell, K. G. B. Nitrile Oxides, Nitrones and Nitronates in Organic Synthesis; VCH: New York, 1988. (c) Padwa, A.; Pearson, W. H. The Chemistry of Heterocyclic Compounds; John Wiley & Sons: New York, 2002; Vol. 59 (Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products).
- (18) Deegan, T. L.; Nitz, T. J.; Cebzanov, D.; Pufko, D. E.; Porco, J. A. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 209–212.
- (19) Wang, Y.; Miller, R. L.; Sauer, D. R.; Djuric, S. W. Org. Lett. 2005, 6, 925–928. and references therein.

CC050044+